Rhythm Pharmaceuticals | SCHEDULE 13G/A: Others
This article indicates a Schedule 13G/A filing for Rhythm Pharmaceuticals, signaling an amendment to a previous beneficial ownership report. The specific details of the amendment are not provided in the snippet, as the content is simply "Document."
Investigation launched into Rhythm Pharmaceuticals' executives for possible self-dealing harming shareholders
Kuehn Law, PLLC has initiated an investigation into Rhythm Pharmaceuticals' officers and directors for potential breaches of fiduciary duties through self-dealing. This legal probe could result in damages for shareholders and corporate governance reforms, prompting long-term shareholders to seek legal counsel. The article highlights concerns about executive accountability and shareholder protection within Rhythm Pharmaceuticals.
ETFs Investing in Rhythm Pharmaceuticals, Inc. Stocks
This article provides a comprehensive list of ETFs that include Rhythm Pharmaceuticals, Inc. stocks in their holdings. The ETFs are sorted by market value and include details such as weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. This information helps investors identify diversified options for investing in Rhythm Pharmaceuticals, Inc. with varying risk profiles.
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced that Health Canada has approved IMCIVREE® (setmelanotide) for weight management in adult and pediatric patients aged 4 years and older with acquired hypothalamic obesity (HO). This marks the first targeted therapy approved in Canada for this condition, which is a rare neuroendocrine disease. The approval is based on the positive results from the pivotal Phase 3 TRANSCEND trial, demonstrating a significant reduction in BMI.
Will Canada Approval Change Rhythm Pharmaceuticals' (RYTM) Narrative
Rhythm Pharmaceuticals received Health Canada approval for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity, expanding its market for rare genetic obesity disorders in Canada. This approval reinforces the company's strategy of focusing on its MC4R obesity franchise to support its rare disease business. While this broadens IMCIVREE's potential patient base, Rhythm Pharmaceuticals still faces the challenge of scaling revenue to overcome significant net losses and R&D expenses, with analysts forecasting substantial revenue and earnings growth by 2029.
Rhythm Pharmaceuticals Gains Health Canada Approval for Imcivree
Rhythm Pharmaceuticals (RYTM) announced that Health Canada has approved its drug Imcivree for weight management. The article notes that a premium subscription is required to read the full details of this MT Newswires report.
Canada approves first targeted treatment for obesity caused by brain injury
Rhythm Pharmaceuticals' drug IMCIVREE (setmelanotide) has received Health Canada approval for treating acquired hypothalamic obesity in adult and pediatric patients aged 4 years and older. This marks the first targeted therapy in Canada for this rare condition, which results from hypothalamic injury and leads to severe weight gain. The approval is based on positive results from the Phase 3 TRANSCEND trial, demonstrating a significant reduction in BMI.
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced that Health Canada has approved IMCIVREE (setmelanotide) for the additional indication of weight management in adult and pediatric patients aged 4 years and older with acquired hypothalamic obesity (HO). This marks IMCIVREE as the first targeted therapy approved in Canada for acquired HO, building on its prior approval for other rare genetic obesity disorders. The approval is based on positive results from the Phase 3 TRANSCEND trial, which demonstrated a significant reduction in BMI.
Is Rhythm Pharmaceuticals (RYTM) Undervalued On Fresh Setmelanotide Data?
Rhythm Pharmaceuticals (RYTM) is under renewed scrutiny following new clinical data on setmelanotide for rare hypothalamic obesity. Despite recent share price declines, the company shows strong long-term shareholder returns and is considered 27.1% undervalued by a popular narrative, driven by expected double-digit revenue growth and an expanding portfolio. However, its high P/S ratio of 28x suggests potential overvaluation compared to the biotech industry average, indicating higher risk if growth expectations falter.
Wolfe Research Initiates Rhythm Pharmaceuticals at Outperform
Wolfe Research has initiated coverage on Rhythm Pharmaceuticals (RYTM) with an Outperform rating. The article, which appears to be premium content, notes that RYTM currently holds an average "buy" rating and a mean price target of $138.59, based on available analyst information. Full details are behind a paywall.
Rhythm Pharmaceuticals (RYTM) CEO sells 50,000 shares under preset plan
Rhythm Pharmaceuticals' CEO, David P. Meeker, exercised options for 50,000 shares of common stock and subsequently sold all 50,000 shares on September 14, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in June 2026. The sales occurred across multiple transactions at weighted average prices ranging from $101.7464 to $105.19 per share.
Rhythm Pharmaceuticals president & CEO Meeker sells $5.13m stock By Investing.com
David P. Meeker, President and CEO of Rhythm Pharmaceuticals (NASDAQ:RYTM), sold approximately $5.13 million worth of common stock on September 14, 2026, after exercising employee stock options. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan. The company's stock is currently trading at $102.44, with InvestingPro indicating it is overvalued.
RHYTHM Pharmaceuticals CEO David P. Meeker Executes Option Exercise and Sells 50,000 Shares
RHYTHM Pharmaceuticals CEO David P. Meeker exercised options for 50,000 shares at $6.05 each on September 14, 2026, and subsequently sold all 50,000 shares in five transactions ranging from $101.75 to $105.19 per share. After these transactions, Meeker's holdings in RHYTHM PHARMACEUTICALS were 239,258 shares and 15,431 derivative securities. This activity significantly altered his reported ownership, with the exercised shares initially representing 17.3% of his total holdings before the sales.
Rhythm Pharmaceuticals president & CEO Meeker sells $5.13m stock
David P. Meeker, President and CEO of Rhythm Pharmaceuticals (NASDAQ:RYTM), sold approximately $5.13 million worth of common stock on September 14, 2026, after exercising employee stock options. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. Despite the stock trading at $102.44, InvestingPro analysis suggests it is overvalued, yet the company recently surpassed Q2 2026 earnings expectations and received a raised price target from Citizens.
Insider lines up multimillion-dollar stock sale at Rhythm Pharmaceuticals (NASDAQ: RYTM)
David Meeker, an insider at Rhythm Pharmaceuticals (RYTM), has filed a Rule 144 notice to sell 50,000 shares of common stock, valued at approximately $5,235,500. These shares will be acquired through the exercise of stock options and are planned to be sold on NASDAQ on or after September 14, 2026. The transaction will be facilitated by Morgan Stanley Smith Barney LLC.
Rhythm Pharmaceuticals Announces New Data Presentations at
Rhythm Pharmaceuticals will present new data at the 64th Annual European Society for Paediatric Endocrinology (ESPE) Meeting regarding their drug setmelanotide. Real-world data from France shows reductions in BMI and hunger in pediatric patients with acquired hypothalamic obesity (HO) treated with setmelanotide for up to 18 months. Phase 3 analyses also demonstrated improvements in cardiometabolic risk indices in patients with acquired HO.
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced new data presentations at the 64th Annual European Society for Paediatric Endocrinology (ESPE) Meeting. The presentations highlighted real-world data showing setmelanotide reduced BMI and hunger in paediatric patients with acquired hypothalamic obesity (HO) over 18 months, as well as Phase 3 data demonstrating improvements in cardiometabolic risk indices. These findings further support setmelanotide's potential impact on patients with acquired HO and other rare MC4R pathway diseases.
An AI drug specialist zeroes in on rare forms of obesity
Superluminal Medicines, an AI drug discovery startup, has secured an additional $60 million in funding to advance its lead candidate for rare forms of obesity into human trials by year-end. The company focuses on G protein-coupled receptors (GPCRs), specifically targeting MC4R, a protein that regulates appetite and energy. This treatment aims to be a safer, daily oral alternative to existing injectable therapies like Rhythm Pharmaceuticals' Imcivree, initially for conditions like Bardet-Biedl syndrome and hypothalamic obesity, with potential expansion to Prader-Willi and general obesity.
Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today
Rhythm Pharmaceuticals (NASDAQ: RYTM) has significantly outperformed the market over the last five years, with an annualized return of 52.06%. An initial investment of $100 in RYTM stock five years ago would now be worth $782.75, highlighting the power of compounded returns. The company currently holds a market capitalization of $7.42 billion.
Deutsche Bank Initiates Rhythm Pharmaceuticals at Hold With $120 Price Target
Deutsche Bank has initiated coverage on Rhythm Pharmaceuticals (RYTM) with a "Hold" rating and set a price target of $120. This announcement comes amid other recent news for the company, including regulatory approvals for its drug Imcivree in Japan and the UK, and recent Q2 2026 earnings results.
Rhythm Pharmaceuticals (RYTM) Stock Looks Overvalued Despite Its 7x Five Year Run
Rhythm Pharmaceuticals (RYTM) stock, despite a sevenfold increase in its share price over the past five years, appears overvalued based on current market multiples. While the recent approval of IMCIVREE in Japan could boost future revenue, the stock's price-to-sales ratio of 32.5x significantly exceeds the biotech industry average, suggesting it has run too far on sales. The article concludes that future returns will depend on the company's ability to convert its pipeline and approvals into sustained commercial success without significant setbacks.
Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story
Rhythm Pharmaceuticals (RYTM) has seen increased attention after Japan approved IMCIVREE for acquired hypothalamic obesity, bolstering its stock performance. Despite a 15.4% undervaluation narrative suggesting a fair value of $134, the company's current P/S ratio of 32.5x is significantly higher than industry averages, indicating potential valuation risk. Investors are advised to scrutinize the growth story against the premium valuation.
Rhythm's Imcivree becomes first approved therapy for acquired hypothalamic obesity in Japan
Rhythm Pharmaceuticals' Imcivree (setmelanotide) has received marketing authorization in Japan for acquired hypothalamic obesity (HO), making it the first approved therapy for this condition in the country. The approval is based on the Phase III TRANSCEND trial, which showed a significant reduction in BMI. Rhythm expects to launch the drug before the end of 2026 and estimates 5,000 to 8,000 patients in Japan could benefit.
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE®
Rhythm Pharmaceuticals announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IMCIVREE® (setmelanotide) for patients with acquired hypothalamic obesity (HO). This makes IMCIVREE the first approved therapy in Japan for this condition, which is estimated to affect 5,000 to 8,000 people in the country. Rhythm expects to launch the treatment by the end of 2026, following pricing determination, with the approval supported by positive Phase 3 trial data.
Rhythm Pharmaceuticals gains Japan approval for obesity therapy
Rhythm Pharmaceuticals received Japanese marketing authorization for its IMCIVREE therapy, an obesity treatment for acquired hypothalamic obesity, targeting 5,000 to 8,000 people in Japan. This approval followed a successful Phase 3 TRANSCEND trial showing an 18.8% reduction in BMI. The company plans to officially launch the therapy in Japan by the end of 2026, pending final pricing agreements.
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
Rhythm Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved IMCIVREE (setmelanotide) for treating acquired hypothalamic obesity (HO). This marks the first therapy approved in Japan for this condition, which is estimated to affect 5,000 to 8,000 patients. The company anticipates launching IMCIVREE in Japan by the end of 2026, pending final pricing determination, following positive results from the Phase 3 TRANSCEND trial.
Japan Grants Marketing Authorization to First Therapy for Rare Obesity Affecting 5,000–8,000 People
Rhythm Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare has granted marketing authorization for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity (HO). This marks the first approved therapy for this condition in Japan, which affects an estimated 5,000–8,000 people. The approval is based on positive results from the Phase 3 TRANSCEND trial, and IMCIVREE is expected to launch in Japan by the end of 2026, pending final pricing.
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Expanded UK Approval For IMCIVREE In Hypothalamic Obesity
Rhythm Pharmaceuticals received expanded UK approval for IMCIVREE to treat acquired hypothalamic obesity, significantly broadening its target patient population. This regulatory development is a positive catalyst for the company, but its impact on revenue and profitability hinges on efficient reimbursement uptake in the UK. While analysts project substantial revenue and earnings growth by 2029, the company faces ongoing operating losses and relies on new capital, necessitating careful evaluation by investors.
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Expanded UK Approval For IMCIVREE In Hypothalamic Obesity
Rhythm Pharmaceuticals received expanded UK approval for IMCIVREE to treat acquired hypothalamic obesity, which broadens its patient population and underscores the drug's clinical impact. This regulatory decision is an incremental positive catalyst, influencing Rhythm's investment narrative and future growth as the company works to secure reimbursement and scale international access for IMCIVREE, amidst ongoing losses and funding needs. Investors should monitor the efficiency of reimbursement uptake, as this will affect revenue potential and potential future capital raises.
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Expanded UK Approval For IMCIVREE In Hypothalamic Obesity
Rhythm Pharmaceuticals recently received expanded UK approval for IMCIVREE to treat acquired hypothalamic obesity, significantly broadening its target patient population. While this is a positive catalyst, the company's future revenue growth and reduced reliance on capital raises depend on efficient international reimbursement uptake. Investors should monitor how quickly new indications translate into reimbursed patients, considering the company's ongoing losses and broad pipeline.
Blue Owl Capital Holdings LP Invests $6.82 Million in Rhythm Pharmaceuticals, Inc. $RYTM
Blue Owl Capital Holdings LP has acquired a new stake of 61,455 shares, valued at approximately $6.82 million, in Rhythm Pharmaceuticals, Inc. This investment represents about 1% of Blue Owl's portfolio and 0.09% of Rhythm Pharmaceuticals. Despite insider sales totaling over $20.7 million in the last 90 days, analysts maintain a "Moderate Buy" rating for RYTM with an average price target of $142.44, following the company's strong Q2 earnings report.
Rhythm Pharmaceuticals (RYTM) Could Be 14% Undervalued Following Its CMO Appointment
Rhythm Pharmaceuticals (RYTM) recently appointed Manher “AJ” Joshi, M.D., as Chief Medical Officer, signaling continued leadership in rare disease drug development. The company is currently trading at US$115.25, which is considered 14% undervalued compared to a narrative fair value of $134, primarily due to its high-growth potential in orphan neuroendocrine disorders and expanded IMCIVREE indications. However, its high P/S ratio of 33.1x suggests investors are paying a premium for future growth, necessitating careful consideration of execution risks and future trial results.
Rhythm (RYTM) CMO reports no company stock holdings
Rhythm Pharmaceuticals, Inc. (RYTM) Chief Medical Officer, Joshi Manher, has filed an initial statement of beneficial ownership (Form 3) indicating no equity transactions or holdings in the company. The filing includes an Exhibit 24 for a Power of Attorney, allowing filings to be made on his behalf. This Form 3 acts as an initial declaration of ownership upon becoming an insider and does not report any stock purchases or sales.
Rhythm Pharmaceuticals (RYTM) grants CMO 50K options expiring 2036
Rhythm Pharmaceuticals (RYTM) has granted its Chief Medical Officer, Manher Joshi, 50,000 stock options with an exercise price of $115.44, expiring in 2036, and 25,000 Restricted Stock Units (RSUs). The stock options vest over four years, while the RSUs vest annually from 2027 to 2030, both contingent on continued service. Following these grants, Joshi directly holds 50,000 options and 25,000 RSUs.
Rhythm Pharmaceuticals (RYTM) Stock Looks Pricey Following Strong IMCIVREE News
Rhythm Pharmaceuticals (RYTM) has seen a significant 5-year return, but its current valuation, particularly its high P/S ratio of 33.1x, suggests it may be overvalued compared to the biotech industry average and its own tailored fair P/S ratio of 19.7x. While recent positive news on IMCIVREE and RM-718 has fueled optimism, investors need to consider whether the stock's current price already fully reflects these developments or if there's still room for upside. The article highlights that the valuation "bakes in a lot of confidence" in future execution and broader adoption.
Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock
Rhythm Pharmaceuticals CTO Joseph Shulman sold 5,079 shares of company stock for over $608,000 after exercising stock options under a Rule 10b5-1 plan. The sale occurred as the stock neared its 52-week high, following strong Q2 2026 performance and a raised price target from Citizens due to successful product launches. The company, despite being unprofitable, has seen significant revenue growth.
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells 5,079 Shares of Stock
Joseph Shulman, an insider at Rhythm Pharmaceuticals (NASDAQ:RYTM), sold 5,079 shares of the company's stock for approximately $608,210, reducing his ownership by over 24%. This sale was executed under a pre-arranged Rule 10b5-1 plan. Despite the insider selling, the company recently reported strong quarterly revenues that exceeded estimates and has a "Moderate Buy" consensus rating from analysts with a positive price target.
Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock
Joseph Shulman, CTO of Rhythm Pharmaceuticals, sold 5,079 shares of company stock for $608,210 on August 13, 2026, after exercising stock options for 2,024 shares. The transactions were conducted under a Rule 10b5-1 trading plan. Despite the stock trading near its 52-week high and significant revenue growth, InvestingPro analysis suggests the stock is overvalued.
Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Alastair Garfield Sells 7,763 Shares
Rhythm Pharmaceuticals (NASDAQ:RYTM) insider Alastair Garfield sold 7,763 shares of the company's stock for approximately $912,696 under a pre-arranged Rule 10b5-1 plan, reducing his direct stake by 77.18%. The company recently reported better-than-expected quarterly results, with a narrower loss of $0.73 per share and revenue up 46.9% year over year. Despite the insider sale, analysts maintain a positive outlook, with a "Moderate Buy" consensus and an average price target of $142.44 against the current price of $115.44.
Rhythm (NASDAQ: RYTM) CTO sells 5,079 shares in 10b5-1 plan
Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, exercised 2,024 stock options at $6.80 per share and subsequently sold 5,079 common shares at $119.75 per share. These transactions, which generated approximately $608,000 in gross proceeds from the sale, were conducted on August 13, 2026, under a Rule 10b5-1 trading plan adopted in December 2025. Following these transactions, Shulman retains 5,945 stock options and 15,915 common shares.
Rhythm Pharmaceuticals (RYTM) Stock Looks Pricey Following Strong IMCIVREE News
Rhythm Pharmaceuticals (RYTM) has seen a significant 5-year return, but its current valuation suggests it might be overpriced, particularly after recent positive news on IMCIVREE and RM-718. The stock trades at a much higher Price/Sales ratio (33.1x) compared to the biotech industry average (10.9x), indicating it's priced for substantial future growth and optimism. While regulatory progress and trial data are encouraging, execution risks related to adoption, reimbursement, and further approvals could challenge maintaining its premium valuation.
Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm Pharmaceuticals has announced the appointment of Manher (Aj) Joshi as its new Chief Medical Officer. This article from Reuters, available on TradingView, provides details on this key leadership change within the pharmaceutical company.
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
Rhythm Pharmaceuticals has announced the appointment of Manher "AJ" Joshi, M.D., as its new Chief Medical Officer, effective August 17, 2026. Dr. Joshi brings over two decades of experience in drug development, regulatory processes, and life-cycle management, having previously served at Soleno Therapeutics, Neurona Therapeutics, and Atara Biotherapeutics. His appointment is expected to bolster Rhythm's efforts in advancing its next-generation MC4R agonists and expanding its leadership in rare neuroendocrine diseases.
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
Rhythm Pharmaceuticals has appointed Manher "AJ" Joshi, M.D., as its new Chief Medical Officer, effective August 17, 2026. Dr. Joshi brings over two decades of experience in drug development, regulatory processes, and lifecycle management, previously serving as Chief Development Officer at Soleno Therapeutics and CMO at Neurona Therapeutics. His appointment is expected to strengthen Rhythm's leadership in rare neuroendocrine diseases and advance its clinical pipeline.
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV
This article provides financial data for Rhythm Pharmaceuticals, Inc. (DUS:1RV) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to revenue forward. It notes that the market is closed with no trades recorded at the time of publication. The content is presented without specific financial figures, serving as a data placeholder from TradingView.
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$8.9 Million in Common Stock
An officer at Rhythm Pharmaceuticals (RYTM.US) recently sold a substantial amount of common stock, totaling US$8.9 million. This transaction indicates a significant insider sale for the company.
Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares
Rhythm Pharmaceuticals' EVP Yann Mazabraud sold 57,000 shares of the company's stock for approximately $6.62 million, reducing his direct stake by over 50%. This transaction occurred under a pre-arranged Rule 10b5-1 trading plan. The company recently reported better-than-expected quarterly revenue and adjusted loss, and analysts maintain a "Moderate Buy" rating with an average price target of $142.44.
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock
Rhythm Pharmaceuticals' EVP, Jennifer Kayden Lee, sold 75,834 shares of the company's stock for approximately $8.9 million, reducing her ownership by 58.3%. This transaction occurred under a pre-arranged Rule 10b5-1 trading plan. The company's stock is trading near its 52-week high, and analysts maintain a "Moderate Buy" rating with an average price target of $142.44.
Rhythm Pharmaceuticals EVP, Jennifer Lee, sells $8.9m in stock
Jennifer Lee, EVP of Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM), sold approximately $8.9 million worth of common stock after exercising options for about $997,036. The sale was executed under a Rule 10b5-1 trading plan as the stock trades near its 52-week high and is considered overvalued by InvestingPro. This follows positive Q2 financial results and a raised price target from Citizens.
Rhythm Pharmaceuticals (RYTM) EVP exercises 56,601 options and sells 75,834 shares
Jennifer Kayden Lee, EVP of Rhythm Pharmaceuticals (RYTM), exercised 56,601 stock options at prices of $24.29 and $6.80, and subsequently sold 75,834 common shares at $117.3818 per share. These transactions, valued at approximately $8.90 million gross proceeds from sales and $997K in exercise costs, were conducted on August 13, 2026, under a pre-established Rule 10b5-1 trading plan. After the transactions, her direct holdings include 36,283 stock options and 0 common shares.
